• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Embecta stock soars on Street-beating Q4, raised 2023 guidance

February 14, 2023 By Sean Whooley

BD Diabetes Spinoff EmbectaEmbecta (Nasdaq:EMBC) shares received a boost today on fourth-quarter results that came in well ahead of the consensus forecast.

Shares of EMBC ticked up 7.9% at $30.67 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 11.3%.

Wall Street’s positive reaction to the results is likely attributable to Embecta’s sizeable guidance increase for 2023.

The company now projects adjusted EPS to range between $2.20 and $2.35. That marks a significant rise from previous expectations of between $1.75 and $2. Embecta also upped its revenue guidance, now projecting between $1.084 billion and $1.107 billion. Its previous range fell between $1.05 billion and $1.073 billion.

The rest of the Q4 results for Embecta

The Parsippany, New Jersey-based diabetes technology developer posted profits of $35.2 million. That amounts to 61¢ per share on sales of $275.7 million for the three months ended Dec. 31, 2022.

Embecta, the BD diabetes spinoff, registered a 64.4% bottom-line slide on a sales decline of 4.7%.

Adjusted to exclude one-time items, earnings per share totaled 96¢. That landed 45¢ ahead of expectations on Wall Street. Sales topped analysts’ estimates as well, as they projected revenues of $262.9 million.

Embecta listed highlights for the quarter, including “continued progress” on its development of a closed-loop insulin delivery system. The patch pump technology, which has FDA breakthrough device designation, targets the type 2 diabetes community. Devdatt (Dev) Kurdikar, Embecta CEO, recently spoke with Drug Delivery Business News to discuss this development, among other things.

“We are pleased with our financial performance in the first fiscal quarter, which exceeded our initial expectations in an operating environment that remains challenging,” Kurdikar said. “During fiscal year 2023, we remain focused on three key strategic priorities: strengthening our base business, separating and standing up Embecta as an independent company, and investing in growth.

“Throughout the first quarter, we made progress on each of these objectives, as we continue setting up Embecta for sustainable success. Given our performance during the first quarter, we are raising our guidance for our key financial reporting metrics.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: embecta

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS